In a meta-analysis of 6 randomized-controlled trials, the LEAD (Liraglutide Efficacy and Action in Diabetes) trials, daily injection of GLP-1RA liraglutide (1.8 mg per day) produced a significant decrease in plasma alanine aminotransferase (ALT) (a liver injury biomarker) in patients with T2DM, and the effect was dose-dependent (no significant difference vs. placebo with liraglutide 0.6 or 1.2 mg). Here, GPT is linked to type 2 diabetes mellitus.